PeptideInfo
العربيةGet the app
☰
Tissue repair researchResearch only

TB-500

The thymosin beta-4 domain sequesters G-actin. Associated actions include migration of endothelial cells and formation of new blood vessels, reduced TNF-alpha and IL-1beta signaling, and stimulation of the Wnt/beta-catenin pathway.

Not medical advice. Educational reference only.

Typical dose
5 mg subcutaneously twice weekly for four weeks, then 2.5 mg subcutaneously weekly
Route
Subcutaneous injection
Cycle
4–8 weeks
Storage
Refrigerate the mixed solution at 2–8 °C; use within 28 days.

What is TB-500?

TB-500 is a synthetic version of an active fragment of thymosin beta-4, a protein containing 43 amino acids that occurs in almost every human cell. The parent protein contributes to actin control, movement of cells and tissue regeneration. Research examines new blood-vessel formation, lower inflammation, greater tissue flexibility and recovery after musculoskeletal injury. TB-500 has no FDA approval, and 503A compounding pharmacies cannot prepare it.

Mechanism of action

The thymosin beta-4 domain sequesters G-actin. Associated actions include migration of endothelial cells and formation of new blood vessels, reduced TNF-alpha and IL-1beta signaling, and stimulation of the Wnt/beta-catenin pathway.

Targets: G-actin · Wnt/beta-catenin pathway · Endothelial cells

Research indications

  • Tissue Repair

    Most effective

    Repair research examines faster wound closure and restoration of injured soft tissues.

  • Gut Health

    Effective

    Gastrointestinal research concerns improved intestinal lining integrity and digestive function.

  • Joint Support

    Effective

    Potential joint effects include reduced inflammation together with greater mobility.

  • Muscle Recovery

    Moderate

    Research explores faster recovery after muscle strains and stress associated with exercise.

Research protocols

These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.

GoalAmountFrequencyRoute
Loading Phase (Week 1–4)5 mgTwice weeklySubcutaneous injection
Maintenance from week 5 onward2.5 mgOnce weeklySubcutaneous injection
Acute Injury Protocol5 mgTwice weekly x 4 wksSubcutaneous injection

Interactions

  • TB-500 / BPC-157

    Compatible

  • NSAIDs (Ibuprofen, Naproxen)

    Caution

  • Corticosteroids

    Caution

  • Anticoagulants

    Monitor

  • GH Secretagogues

    Compatible

  • NAD+

    Compatible

How to reconstitute and inject

Diluent: Use only bacteriostatic water; avoid saline because precipitation can occur.

  1. Let your refrigerated TB-500 vial stand for 15–20 minutes so it reaches room temperature before mixing.
  2. Disinfect the rubber stopper using an alcohol swab. Wait for all of the alcohol to air-dry.
  3. Measure the calculated bacteriostatic water volume with a sterile syringe. Use BAC water only; saline can lead to precipitation.
  4. Deliver the water slowly against the vial’s inner wall. Keep the stream from striking the powder directly.
  5. Mix by gently rotating the vial in circles. Avoid vigorous shaking, which can break down the peptide.
  6. Wait 2–3 minutes until dissolution is complete. Inspect the liquid for a clear appearance without color.
  7. Measure your calculated dose in an insulin syringe for administration beneath the skin.
  8. Choose your abdomen, upper arm or thigh for subcutaneous administration. Change sites between injections to help prevent lipodystrophy.
  9. Keep the mixed vial at 2–8 °C in the refrigerator. Use the solution within 28 days of preparation.

What to expect

Week 1–2
Early changes may include less inflammation, pain and swelling around the affected tissue.
Week 2–4
Mobility of the tissue may improve as discomfort diminishes and healing begins to accelerate.
Week 4–8
More substantial recovery milestones may accompany stronger tissue repair and better function.
Week 8–12
Later expectations include healing approaching completion in many cases, with improved tissue integrity and strength; this is not a guaranteed outcome.

Side effects and safety

  • Mild nausea at larger doses
  • Discomfort or redness around the injection area
  • Lightheadedness or dizziness · Rare
  • Possible changes in blood pressure; monitor it if you have hypertension

TB-500: not approved in the US; 503A compounding banned.

Regulatory status

  • US

    Not approved

    FDA — TB-500 is unapproved for human treatment and cannot be prepared by 503A compounding pharmacies. Telehealth prescribing is not applicable.

    Rx required
    No
    503A
    Banned
    Telehealth
    N/A

Frequently asked questions

How do TB-500 and BPC-157 differ?

TB-500 research emphasizes sequestration of actin and movement of endothelial cells, with a more systemic repair rationale. BPC-157 research emphasizes local growth-factor signaling and nitric oxide modulation, particularly in the gut. Their different proposed actions are the rationale for combining them, rather than proof that either repairs injuries in people.

Which schedules are discussed?

Loading schedules commonly use subcutaneous 5 mg doses twice each week over four weeks. Maintenance then uses 2.5 mg weekly, and research cycles commonly last 4–8 weeks depending on the injury or protocol. These are research amounts, not approved doses, and the acute-injury schedule also uses 5 mg twice weekly for four weeks.

What is known about combining it with BPC-157?

The pair is considered compatible in research discussions because growth-factor and gut effects may complement actin-related and blood-vessel effects. Human clinical trials have not evaluated the combination. Potential synergy therefore remains unproven; consult a healthcare professional before combining these peptides. Tolerability is generally favorable in research settings.

References

  1. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. (2012)

    PMID 22074294DOI 10.1517/14712598.2012.634793

  2. Recombinant thymosin beta 4 can promote full-thickness cutaneous wound healing. (2007)

    PMID 17923415DOI 10.1016/j.pep.2007.08.011

  3. Thymosin beta 4 and wound healing: a multifunctional peptide (2010)

  4. Thymosin β4 promotes angiogenesis, healing, and cardiac function (2012)

  5. Thymosin beta-4 studies on ClinicalTrials.gov (2024)

  6. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. (2026)

    PMID 41476424DOI 10.1177/03635465251357593

  7. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. (2026)

    PMID 41490200DOI 10.5435/JAAOSGlobal-D-25-00236